We have also demonstrated disease-modifying effects in several families of huprine-based hybrid compounds, which, apart from displaying very potent AChE inhibitory activity (IC50 values towards human AChE in the single-digit nanomolar range), modulate several key factors involved in the underlying mechanisms of AD when administered to APP/PS1 mice, including amyloid burden, neuroinflammation and epileptogenic activity, and enhance cognition [15,16,17]. Here, ACHE is linked to Alzheimer disease.